Cantor Fitzgerald Forecasts ARTV FY2024 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($3.63) for the year. Cantor Fitzgerald has a “Overweight” rating and a $23.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.49) per share.

ARTV has been the subject of several other reports. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Wedbush reiterated an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, August 30th. Finally, TD Cowen assumed coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Price Performance

Shares of ARTV opened at $11.30 on Monday. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31. The company has a fifty day simple moving average of $12.50.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24).

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in ARTV. BNP Paribas Financial Markets acquired a new position in Artiva Biotherapeutics in the third quarter worth about $42,000. MetLife Investment Management LLC acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $135,000. Barclays PLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $304,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $623,000. Finally, Acuta Capital Partners LLC acquired a new position in Artiva Biotherapeutics in the third quarter worth $680,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.